In The News Posted December 9, 2019 Share Posted December 9, 2019 SHANGHAI, Dec. 9, 2019 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage biopharmaceutical company committed to discovering and developing a combined platform of Chimeric Antigen Receptor T (CAR-T) cell therapies and monoclonal antibodies for cancer, today announced that one of its... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.